Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 28,273 shares at $50.00 ($414K) on 2024-12-10, disclosed to the SEC on 2024-12-11.
Scheduled sale ($414k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 20,000 | $0 | 0.0% |
| 2 | $50.00 | 8,273 | $414K | 100.0% |
| Total | $14.63 avg | 28,273 | $414K | 100% |
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |
| RARE | SELL | 2024-08-07 | $1.0M | — | Filing → |